AbbVie (ABBV)
227.97
+3.03 (1.35%)
Upcoming Events
Latest Headlines
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026 8:00 AM - PR NewsWire
Form SD AbbVie Inc.
June 1, 2026 5:17 PM - SEC Filing
AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations
May 29, 2026 8:00 AM - StreetInsider
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
May 29, 2026 8:00 AM - PR NewsWire
FDA approves AbbVie's DECNUPAZ for rare blood cancer treatment
May 27, 2026 6:18 PM - StreetInsider
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatme
May 27, 2026 6:18 PM - PR NewsWire
FDA approves AbbVie's pivekimab sunirine-PVZY for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
May 27, 2026 3:38 PM - StreetInsider
Form 144 AbbVie Inc. Filed by: Alpern Robert J
May 26, 2026 4:19 PM - SEC Filing
AbbVie receives positive EU committee opinion for hepatitis C drug
May 22, 2026 8:00 AM - StreetInsider
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
May 22, 2026 8:00 AM - PR NewsWire
AbbVie to present oncology pipeline data at 2026 ASCO meeting
May 22, 2026 5:31 AM - StreetInsider
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
May 21, 2026 6:46 PM - PR NewsWire
Allergan Aesthetics receives positive opinion for Boey botulinum toxin
May 21, 2026 4:10 PM - StreetInsider
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
May 21, 2026 4:10 PM - PR NewsWire
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Abbvie (ABBV) PT Lowered to $235 at Evercore ISI
May 15, 2026 7:15 AM - StreetInsider
Abbvie (ABBV) PT Raised to $298 at Piper Sandler
May 14, 2026 7:30 AM - StreetInsider
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 8:33 AM - StreetInsider
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026 8:30 AM - Globe NewsWire
Form 8-K AbbVie Inc. For: May 08
May 12, 2026 5:02 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: FALK THOMAS J
May 12, 2026 5:01 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Quaggin Susan E
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Roberts Rebecca B
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: MEYER MELODY B
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: FREYMAN THOMAS C
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: RAPP EDWARD J
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Davis Jennifer L.
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Hart Brett J
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: WADDELL FREDERICK H
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: BURNSIDE WILLIAM H.L.
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: AUSTIN ROXANNE S
May 12, 2026 5:00 PM - SEC Filing
Form 10-Q AbbVie Inc. For: Mar 31
May 8, 2026 12:30 PM - SEC Filing
Health officials explore restrictions on certain SSRI antidepressants - Reuters
May 8, 2026 12:04 PM - StreetInsider
AbbVie to Present at the Bank of America Securities Healthcare Conference
May 6, 2026 8:00 AM - PR NewsWire
AbbVie presents inflammatory bowel disease data at medical conference
May 5, 2026 8:05 AM - StreetInsider
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
May 5, 2026 8:05 AM - PR NewsWire
NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD
May 5, 2026 8:00 AM - BizWire
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
April 30, 2026 3:00 PM - Globe NewsWire
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
April 30, 2026 9:01 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $278 at Morgan Stanley
April 30, 2026 7:57 AM - StreetInsider
Abbvie (ABBV) PT Raised to $265 at Canaccord
April 30, 2026 6:35 AM - StreetInsider
BofA Securities Upgrades Abbvie (ABBV) to Buy
April 30, 2026 6:06 AM - StreetInsider
Abbvie (ABBV) PT Raised to $244 at Goldman Sachs
April 30, 2026 4:25 AM - StreetInsider
Form SCHEDULE 13G AbbVie Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:39 PM - SEC Filing
AbbVie shares gain on earnings beat, raised guidance
April 29, 2026 8:09 AM - StreetInsider
Form 8-K AbbVie Inc. For: Apr 29
April 29, 2026 7:50 AM - SEC Filing
AbbVie (ABBV) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
April 29, 2026 7:48 AM - StreetInsider
AbbVie Reports First-Quarter 2026 Financial Results
April 29, 2026 7:47 AM - PR NewsWire
AbbVie Q1 earnings preview: analysts eye immunology growth trends
April 29, 2026 12:00 AM - StreetInsider
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
April 28, 2026 8:00 AM - PR NewsWire
EvolveImmune receives $18 million milestone payment from ABBV partnership
April 28, 2026 7:01 AM - StreetInsider
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
April 28, 2026 7:00 AM - Globe NewsWire
AbbVie submits FDA application for SKYRIZI subcutaneous dosing
April 27, 2026 8:05 AM - StreetInsider
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
April 27, 2026 8:05 AM - PR NewsWire
US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)
April 23, 2026 4:35 PM - StreetInsider
FDA requests more manufacturing data for AbbVie's botox alternative
April 23, 2026 4:06 PM - StreetInsider
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
April 23, 2026 4:05 PM - PR NewsWire
Abbvie (ABBV) PT Lowered to $294 at Piper Sandler
April 22, 2026 5:15 PM - StreetInsider
AbbVie to build $1.4 billion manufacturing campus in North Carolina
April 22, 2026 12:28 PM - StreetInsider
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
April 22, 2026 12:03 PM - PR NewsWire
Canaccord Starts Abbvie (ABBV) at Buy, PT set at $262
April 20, 2026 4:36 PM - StreetInsider
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
April 14, 2026 8:50 AM - PR NewsWire
Abbvie (ABBV) PT Lowered to $232 at Evercore ISI
April 13, 2026 10:11 AM - StreetInsider
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Haisco signs exclusive pain medicine license deal with AbbVie
April 13, 2026 2:25 AM - StreetInsider
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
April 13, 2026 2:24 AM - PR NewsWire
AbbVie presents phase 2 ovarian cancer trial data at SGO meeting
April 12, 2026 7:15 AM - StreetInsider
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
April 12, 2026 7:15 AM - PR NewsWire
RBC Capital Reiterates Outperform Rating on Abbvie (ABBV)
April 10, 2026 8:36 AM - StreetInsider
Abbvie (ABBV) PT Raised to $249 at Guggenheim
April 10, 2026 6:56 AM - StreetInsider
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
April 8, 2026 8:01 AM - PR NewsWire
Abbvie (ABBV) PT Lowered to $240 at Cantor Fitzgerald on Bad Sentiment
April 8, 2026 7:31 AM - StreetInsider
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
April 7, 2026 1:04 PM - PR NewsWire
Form 8-K AbbVie Inc. For: Apr 03
April 3, 2026 4:06 PM - SEC Filing
Form 4 AbbVie Inc. For: Mar 31 Filed by: Alpern Robert J
April 2, 2026 5:01 PM - SEC Filing
Form 4 AbbVie Inc. For: Mar 31 Filed by: Quaggin Susan E
April 2, 2026 5:01 PM - SEC Filing
Form 4 AbbVie Inc. For: Mar 31 Filed by: RAPP EDWARD J
April 2, 2026 5:01 PM - SEC Filing
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
March 31, 2026 8:05 AM - PR NewsWire
AbbVie to Host First-Quarter 2026 Earnings Conference Call
March 31, 2026 8:00 AM - PR NewsWire
Allergan Aesthetics presents data on investigational neurotoxin at AAD
March 30, 2026 8:01 AM - StreetInsider
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology
March 30, 2026 8:00 AM - PR NewsWire
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
March 27, 2026 10:00 AM - PR NewsWire
Form SCHEDULE 13G/A AbbVie Inc. Filed by: VANGUARD GROUP INC
March 26, 2026 3:06 PM - SEC Filing
Allergan Aesthetics presents 21 research posters at Monaco medical congress
March 26, 2026 5:45 AM - StreetInsider
Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
March 26, 2026 4:00 AM - PR NewsWire
Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
March 26, 2026 3:00 AM - PR NewsWire
NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026
March 24, 2026 8:00 AM - BizWire
AbbVie Named Official Pharmaceutical Partner of Major League Baseball
March 24, 2026 8:00 AM - PR NewsWire
Form ARS AbbVie Inc. For: Dec 31
March 23, 2026 5:10 PM - SEC Filing
Form DEFA14A AbbVie Inc.
March 23, 2026 5:02 PM - SEC Filing
Form DEF 14A AbbVie Inc. For: May 08
March 23, 2026 4:59 PM - SEC Filing
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
March 19, 2026 3:00 AM - PR NewsWire
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
March 12, 2026 6:55 AM - StreetInsider
Form 4/A AbbVie Inc. For: Feb 27 Filed by: Purdue David Ryan
March 11, 2026 5:00 PM - SEC Filing
Form PRE 14A AbbVie Inc. For: Mar 09
March 9, 2026 4:32 PM - SEC Filing
William Blair Reiterates Outperform Rating on Abbvie (ABBV): "competitive across the amylin class"
March 9, 2026 11:52 AM - StreetInsider
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV): today's data "reflective of an opportunity to diversify its business beyond the I&I"
March 9, 2026 9:35 AM - StreetInsider
AbbVie obesity drug shows weight loss in early-stage trial
March 9, 2026 8:00 AM - StreetInsider
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
March 9, 2026 8:00 AM - PR NewsWire
Full Article List
